Medicare Drug Costs in 2026: What Seniors Need to Know

2026 marks the most significant year for Medicare drug costs in the program's two-decade history. The Inflation Reduction Act's $2,000 annual out-of-pocket cap is now fully in effect, drug price negotiations have expanded to 15 additional medications, and Part D premiums are stabilized through federal subsidies. Here's everything you need to know about what Medicare prescription drugs cost in 2026 — and where the money actually goes.

The $2,000 Out-of-Pocket Cap: A Game-Changer

For the first time in Medicare Part D history, beneficiaries now have a hard cap on annual out-of-pocket prescription drug spending. Before the Inflation Reduction Act, there was no upper limit — patients with cancer, autoimmune diseases, or other conditions requiring specialty drugs could face $10,000 or more in annual costs. Some Medicare beneficiaries were spending more on medications than on their mortgage.

The $2,000 cap, which took full effect January 1, 2025, fundamentally restructures the Part D benefit. Once a beneficiary hits $2,000 in out-of-pocket costs for the year, their plan covers 100% of remaining drug costs. CMS estimates this saves the average affected beneficiary approximately $1,500 per year, with patients on the most expensive specialty drugs saving $5,000–$10,000 annually.

There's also a new option to spread costs: the Medicare Prescription Payment Plan lets beneficiaries pay their out-of-pocket costs in monthly installments rather than large lump sums at the pharmacy counter. For someone taking an expensive drug in January, this can mean the difference between $800 upfront and $167 per month.

Drug Price Negotiation: Round Two

The IRA gave Medicare the power to negotiate prices directly with pharmaceutical manufacturers — something the program had been legally prohibited from doing since its creation in 2003. In 2026, the second round of negotiations kicks in, adding 15 more drugs to the 10 already negotiated in 2025.

The first 10 negotiated drugs — including Eliquis, Jardiance, Xarelto, and Januvia — saw price reductions averaging 38-79% off their list prices, effective this year. For Eliquis alone, the negotiated price dropped from roughly $521 per month to $231. Given that Eliquis is Medicare's single most expensive drug at $7.75 billion annually, even modest reductions translate to billions in savings.

The 15 new drugs selected for 2026 negotiation include several high-cost specialty medications and widely-prescribed chronic disease treatments. Final negotiated prices will take effect in 2027, but the announcement alone has already pressured manufacturers to offer voluntary discounts.

2026 Part D Premium Landscape

Monthly Part D premiums in 2026 average $36.78, held artificially low by a federal subsidy provision in the IRA that prevents premium increases above a set threshold through 2029. Without this subsidy, actuaries estimated premiums would have jumped 15-20% due to the cost shift from the out-of-pocket cap — plans now absorb costs that previously fell on patients in the catastrophic phase.

The Part D deductible for 2026 is $590 for standard plans (up from $545 in 2025). Low-income subsidy (LIS) beneficiaries — roughly 13 million people, or about one in four Part D enrollees — continue to have minimal or no cost-sharing.

Premium variation remains significant. The cheapest plans in some regions start below $10/month, while enhanced plans with broader formularies can exceed $100/month. Our data shows that plan choice matters enormously: state-level spending patterns reveal that beneficiaries in high-cost states often pay more even for equivalent drugs.

Where Does Part D Money Go in 2026?

Based on 2023 data (the most recent complete CMS release), Medicare Part D generated $275.6 billion in total drug costs across 1.38 million prescribers. Projected 2026 spending, accounting for drug price negotiations and the out-of-pocket cap, is estimated at $290–$310 billion total — a slower growth rate than the 8-10% annual increases of recent years, but still an enormous sum.

The cost concentration is staggering. Just 20 drugs account for over 22% of total Part D spending. GLP-1 receptor agonists like Ozempic and Wegovy continue their explosive growth trajectory, with the GLP-1 class now representing the fastest-growing cost category in Medicare. If CMS expands Part D coverage to include obesity indications for GLP-1 drugs — a decision expected in late 2026 — total spending could surge by an additional $30-50 billion annually.

The Insulin Story

The $35 monthly insulin cap, one of the IRA's most popular provisions, continues in 2026. This provision caps out-of-pocket insulin costs at $35 per month per insulin product, regardless of how many units a patient uses. Before this cap, some Medicare beneficiaries were paying $400-$600 per month for insulin — forcing dangerous rationing.

The cap applies to all Part D-covered insulin products. Combined with manufacturer discount programs and the broader out-of-pocket cap, 2026 represents the most affordable year for insulin in Medicare history.

What's Still Expensive

Despite the reforms, significant cost pressures remain:

• Specialty drugs — Biologics for cancer, autoimmune conditions, and rare diseases continue to launch at $100,000+ per year. The out-of-pocket cap helps patients, but shifts costs to plans and taxpayers.
• Brand-name holdouts — As our brand vs generic analysis shows, brand drugs cost 10x more on average. Some prescribers still write 90%+ brand prescriptions when generics exist.
• GLP-1 growth — Ozempic, Wegovy, Mounjaro, and Zepbound collectively represent a cost tsunami for Part D. If obesity coverage expands, this becomes the largest single cost driver in Medicare.
• New gene therapies — Cell and gene therapies entering the market in 2025-2026 carry prices of $1-3 million per treatment. While Part B typically covers these, some oral gene therapies may hit Part D formularies.

How Costs Vary by State

Medicare drug costs aren't uniform across the country. Our state-by-state rankings show dramatic variation: per-capita Part D spending in the highest-cost states is nearly triple that of the lowest-cost states. Factors include provider prescribing patterns, disease prevalence, rural vs. urban dynamics, and the influence of regional pharmacy benefit managers.

States with older populations, higher chronic disease burdens, and more geographic prescribing disparities tend to have the highest per-capita costs. Our data tools let you generate a report card for any state to see exactly how it compares.

What Comes Next

The IRA's drug pricing provisions phase in over several years. By 2029, up to 20 drugs per year will be subject to negotiation. The out-of-pocket cap is permanent and indexed to inflation. The premium stabilization subsidy expires after 2029, which could trigger significant premium increases unless Congress acts.

Perhaps the biggest wildcard is the potential expansion of Part D to cover anti-obesity medications. With over 40% of Medicare beneficiaries classified as obese and GLP-1 drugs showing cardiovascular benefits beyond weight loss, the clinical case is strong — but the fiscal impact could reshape the entire program.

For the most granular view of where Medicare drug dollars flow, explore our drug database, search specific prescribers, or use our savings calculator to estimate potential generic switching savings in your area.